$SMR Starting to Bounce off of Double Bottom.

Anthropic is now directly leasing data centers with $GOOGL guaranteeing the payments. They're telling you exactly where the money is flowing (data centers & neoclouds): 1. $IREN - IREN $9.7B Microsoft contract. $3.4B NVIDIA AI cloud contract. 5GW infrastructure partnership with NVIDIA. Expanding to 150,000 GPUs by year-end including 50,000 NVIDIA B300s. Targeting $3.7B ARR.

2X LONG AND SHORT SPACEX ETFS LAUNCHING ON MONDAY Watch out for this on Monday The 2x Long and Short SpaceX ETFs will begin trading ... here are the tickers to watch out for from Leverage Shares - $SPCH - 2x Long SpaceX ETF - $SSPC - 2x Short SpaceX ETF I heard a rumor there is a chance they could begin trading in pre market trading Bookmark this post Disclosure: @LeverageETFs is a SMN Partner. This post is for informational purposes only, not investment advice.

Watchlist $AORT $SMR $INFQ $IREN $NVDA $ABCL $SLNH

It was a historic day for markets. Over 500 million shares of SpaceX, $SPCX, were traded today, with volume exceeding $80 BILLION. SpaceX is now the 7th largest public company in the world. Congratulations to all!

Wall Street just wiped 45% off $AORT over a transient guidance revision, fundamentally mispricing a newly formed clinical monopoly. While the market obsesses over near-term floating debt and lumpy hospital purchasing cycles, Artivion quietly became the only company on earth with a complete endovascular portfolio for aortic arch surgery. Here is a breakdown of why this aggressive sell-off is a massive structural pricing error. 📉👇 #MedTech auth.flash.stocksentinel.ai/…

Artivion Inc $AORT has strategically transformed into a highly defensible pure-play monopoly focused on life-saving treatments for complex aortic diseases. The recent acquisition of Endospan and its groundbreaking NEXUS system makes them the only company globally offering a complete suite of open, hybrid, and endovascular aortic arch solutions. While lowered short-term guidance and high-interest debt from the acquisition recently triggered a steep stock sell-off, the unyielding clinical demand and impending FDA approvals suggest the current valuation offers massive asymmetric upside. Will the highly anticipated commercial expansion in 2027 generate the robust free cash flow needed to rapidly deleverage their balance sheet before higher-for-longer interest rates erode their margins?

$AORT added. Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia. Website artivion.com

Retail investors are moving to the sidelines: Retail investors sold stocks for 3 consecutive days ending Wednesday, the first such streak since the 2020 pandemic. On Monday alone, retail outflows were the highest since November 2023. Semiconductors and AI-related stocks saw the largest sales during this period. On Wednesday, Micron, $MU, saw -$169.4 million in sales, followed by AMD, $AMD, at -$38.7 million and Marvell, $MRVL, at -$35.8 million. This comes after individual investors have bought single stocks during nearly every trading session in 2026 before this week. Retail investors are cashing in gains.